Cancer: Lymphoma

  Manage Alerts
Collapse Summary Pipeline Information
 Disease Dashboard for Lymphoma
11 - All unpartnered indications 8 - All partnered indications 1 - All unpartnered indications 4 - All partnered indications 6 - All unpartnered indications 4 - All partnered indications 44 - All unpartnered indications 20 - All partnered indications 16 - All unpartnered indications 5 - All partnered indications
60 36 5 3 1
5 - Phosphoinositide 3-kinase (PI3K) delta 5 - Phosphoinositide 3-kinase (PI3K) 7 - CD19 10 - Histone deacetylase (HDAC) 12 - CD20
Preclinical = Research, IND, Phase 0, Pilot;
Phase I = Phase I, Phase I/II;
Phase II = Phase II, Phase II/III;
Phase III = Pivotal, Phase III, Registration;
Market = Phase IV, Approved not yet marketed, Marketed
 Pipeline Summary for Lymphoma
 Pipeline Details for Lymphoma
Collapse Summary Deals Information
 Deals Summary for Lymphoma
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

41

$53,195.8M

$16,259.5M

$3,038.8M


 Deals Details for Lymphoma
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone